Filing Flows › Procept BioRobotics (PRCT) › Q3 2025
Procept BioRobotics (PRCT) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 5, 2025
Procept BioRobotics (PRCT) reported revenue of $83.3M for the third quarter 2025 (Q3 2025), +43% from a year earlier and +5% from the quarter before. Operating margin was -27.8%, net loss $21.4M (25.7% of revenue).
Procept BioRobotics, Q3 2025: revenue $83.3M (+43% year over year), operating margin -27.8%, net loss $21.4M, operating cash flow −$6.6M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $83.3M | +5% | +43% |
| Operating profit | −$23.2M | — | — |
| Net earnings | −$21.4M | — | — |
| Operating cash flow | −$6.6M | — | — |
What changed
Revenue was $83.3M in Q3 2025, up 43% year over year and up 5% from the previous quarter.
Gross margin was 64.8%, up 1.6 points from a year earlier. Operating costs exceeded revenue by $23.2M, an operating margin of -27.8%. Operating expenses grew 30% against revenue growth of 43%. The fastest-growing cost line was SG&A (+38%). The quarter ended with a net loss of $21.4M, wider than the previous quarter's $19.6M loss.
Operating cash flow was −$6.6M. Non-cash charges added back $1.6M of depreciation and amortization and $14.5M of share-based compensation. Working capital and other items used $1.3M. Capital expenditures of $2.9M exceeded it, leaving free cash flow of −$9.5M.
Questions
What was Procept BioRobotics' revenue in the third quarter 2025?
Procept BioRobotics (PRCT) reported revenue of $83.3M for the third quarter 2025 (Q3 2025), +43% from a year earlier and +5% from the quarter before.
Was Procept BioRobotics profitable in the third quarter 2025?
Operating loss was $23.2M (-27.8% of revenue) and net loss $21.4M.